Commercial Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening Pharmaceutical TechnologySales for Lilly blew past expectations in the quarter as demand for weight loss treatments showed no signs of abating.Read full story pharminent May 1, 2026 (Last updated: May 1, 2026) Pharmaceutical Technology Sales for Lilly blew past expectations in the quarter as demand for weight loss treatments showed no signs of abating. Read full story Post navigation Previous: BMS brings the buzz around late-stage readouts amid a so-so Q1Next: LEO Pharma to acquire gene therapy company Replay Related Stories Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026
